Format

Send to

Choose Destination
J Pharm Biomed Anal. 2014 Nov;100:230-235. doi: 10.1016/j.jpba.2014.08.011. Epub 2014 Aug 15.

Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry.

Author information

1
AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology and CIC-1421, F-75013 Paris, France.
2
AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology and CIC-1421, F-75013 Paris, France; Sorbonne University, UPMC Univ Paris 06, Faculty of Medicine, Department of Pharmacology and UMR ICAN 1166, F-75013 Paris, France; INSERM, CIC-1421 and UMR ICAN 1166, F-75013 Paris, France.
3
AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology and CIC-1421, F-75013 Paris, France. Electronic address: noel.zahr@psl.aphp.fr.

Abstract

A sensitive and accurate liquid chromatography method with mass spectrometry detection was developed and validated for the quantification of dabigatran (Pradaxa(®)) and rivaroxaban (Xarelto(®)). (13)C6-dabigatran and (13)C6-rivaroxaban were used as the internal standard. A single-step protein precipitation was used for plasma sample preparation. This method was validated with respect to linearity, selectivity, inter- and intra-day precision and accuracy, limit of quantification and stability. The lower limit of quantification was 2.5ng/mL for both drugs in plasma.

KEYWORDS:

Dabigatran; LC–MS/MS; Mass spectrometry; Rivaroxaban; TSOAC

PMID:
25173108
DOI:
10.1016/j.jpba.2014.08.011
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center